Tropical Doctor > Volume 38, Number 1 > Pp. 7-11

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Orem, J. Articles by Weiderpass, E. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Articles

Current investigations and treatment of Burkitt's lymphoma in Africa

Jackson Orem M.B., Ch.B.   ^*    Edward Katongole Mbidde M.B., Ch.B.   ^*   Elisabete Weiderpass MD PhD    

^* Uganda Cancer Institute, Mulago Hospital, Makerere University School of Medicine, Plot 6 Lourdel Road, Wandegeya, PO Box 7272, Kampala, Uganda; Department of Medical Epidemiology and Biostatistics, Karolinska Institute, SE 171 77 Stockholm, Sweden; The Cancer Registry of Norway, Oslo, Norway

Correspondence to: Dr Elisabete Weiderpass, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, PO Box 281, SE 171 77 Stockholm, Sweden Email: elisabete.weiderpass.vainio{at}KI.SE

We reviewed the scientific literature on Burkitt's lymphoma (BL) in Africa in order to provide information on the current status of clinical care and the existing research challenges. BL epidemiology led to the discovery of the Epstein Barr virus, an important cause of several viral illnesses and malignancies. The incidence of BL has increased in the endemic areas of Africa, overlapping with the epidemic of HIV and increase of malaria. The impact of this on the clinical care of BL in the region is therefore of interest, especially in HIV-infected children. Rapid methods must be developed which enable the correct diagnosis to be made. It is important to improve supportive care to allow fairly aggressive treatment, to research into salvage therapy for those who fail first-line treatment, and to develop less toxic drug combinations for HIV-infected patients. Documentation of HIV status through counselling should be offered to all patients.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?